Neuronetics, Inc. STIM
2.18 USD +0.03 (+1.40%)
At closeNov 9, 2026, 7:52 PM EST
2.18 0.00 0.00%
After hours · Nov 9, 7:52 PM ET
1.90 Day range 2.39
0.80 52-week range 3.44
- YTD
- +57.97%
- 1 year
- -4.39%
News
benzinga.com B. Riley Securities Maintains Buy on Neuronetics, Raises Price Target to $6 B. Riley Securities analyst Madison El-Saadi maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.
seekingalpha.com Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript
globenewswire.com Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through…
marketbeat.com Neuronetics Q3 Earnings Call Highlights Neuronetics NASDAQ: STIM reported third-quarter 2026 revenue growth, wider gross margin and a return to positive adjusted EBITDA, citing record NeuroStar system sales and continued revenue-cycle…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
zacks.com Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates Neuronetics (STIM) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.13 per share a year ago.
benzinga.com Neuronetics Q3 2026 Earnings Call Transcript Neuronetics (NASDAQ:STIM) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Neuronetics Q3 EPS $(0.02) Beats $(0.09) Estimate, Sales $41.962M Beat $40.425M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.09) by 77.78 percent. This is a 84.62 percent increase over losses of $(0.13)…
benzinga.com Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$164.000M vs $162.025M Est Neuronetics (NASDAQ:STIM) affirms FY2026 sales outlook from $160.000 million-$164.000 million to $160.000 million-$164.000 million vs $162.025 million estimate.
globenewswire.com Neuronetics Reports Third Quarter 2026 Financial and Operating Results MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology…- benzinga.com B. Riley Securities Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5 B. Riley Securities analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…
benzinga.com Neuronetics Narrows FY2026 Sales Guidance from $160.000M-$166.000M to $160.000M-$164.000M vs $161.125M Est Neuronetics (NASDAQ:STIM) narrows FY2026 sales outlook from $160.000 million-$166.000 million to $160.000 million-$164.000 million vs $161.125 million estimate.
benzinga.com Neuronetics Q2 EPS $(0.05) Beats $(0.13) Estimate, Sales $41.568M Beat $40.175M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.13) by 58.33 percent. This is a 66.67 percent increase over losses of $(0.15)…- benzinga.com Neuronetics Appoints Nir Naor CFO, Effective July 23, Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional…
benzinga.com Why Is Neuronetics Stock Soaring Monday? BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million. Advanced Biomed (NASDAQ:ADVB) stock…
- benzinga.com BTIG Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5 BTIG analyst Sam Eiber initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
benzinga.com Neuronetics Collaborates With ANT Neuro To Expand NeuroStar Advanced Therapy System Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…- benzinga.com Full Transcript: Neuronetics Q1 2026 Earnings Call
benzinga.com Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$166.000M vs $162.467M Est Business OutlookFor the second quarter of 2026, the Company expects total revenue growth in the mid-single digits.For the full year 2026, Neuronetics continues to expect:Total revenue between $160…- benzinga.com Neuronetics Q1 EPS $(0.16) Beats $(0.17) Estimate, Sales $34.454M Beat $34.183M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 23.81 percent increase over losses of $(0.21)…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan This week's deal activity spans gaming, healthcare, energy, and private equity, with activist sales pushes and a slew of bankruptcies.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Neuronetics Initiates Workforce Reduction Impacting Up To 5% Of Employees, Expects ~$200K Restructuring Charges And ~$2.5-$3M Annualized Savings On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees. The reduction is part of a broader effort…- benzinga.com Neuronetics CFO Steven E. Pfanstiel To Depart, Effective May 1; Reiterates Q1, FY26 Outlook Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from…
- benzinga.com Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $3 Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $7 to $3.
- benzinga.com Neuronetics Sees FY2026 Sales $160.000M-$166.000M vs $164.167M Est Neuronetics (NASDAQ:STIM) sees FY2026 sales of $160.000 million-$166.000 million vs $164.167 million analyst estimate.
benzinga.com Neuronetics Q4 EPS $(0.10) Beats $(0.11) Estimate, Sales $41.777M Beat $40.667M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 6.54 percent. This is a 70.59 percent increase over losses of $(0.34)…- benzinga.com Earnings Scheduled For March 17, 2026
- benzinga.com Peering Into Neuronetics Inc's Recent Short Interest
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Teradata Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
benzinga.com Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On? Neuronetics shares jumped 41% in after-hours trading following strong preliminary fourth-quarter 2025 revenue results.- benzinga.com Neuronetics Reports Q4 Preliminary Revenue $41.8M, FY25 Revenue $149.2M Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the…
benzinga.com Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November - benzinga.com Neuronetics Lowers FY2025 Sales Guidance from $149.000M-$155.000M to $147.000M-$150.000M vs $151.030M Est Neuronetics (NASDAQ:STIM) lowers FY2025 sales outlook from $149.000 million-$155.000 million to $147.000 million-$150.000 million vs $151.030 million estimate.
benzinga.com Neuronetics Q3 EPS $(0.13) Misses $(0.10) Estimate, Sales $37.297M Miss $38.055M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 26.21 percent. This is a 70.45 percent increase over losses of…
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com New York Medicaid To Cover Neuronetics' TMS Therapy For Major Depressive Disorder Starting October 2025 Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…
- benzinga.com Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $7 Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $8 to $7.
- benzinga.com Neuronetics Affirms FY2025 Sales Guidance of $149.000M-$155.000M vs $150.673M Est Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $149.000 million-$155.000 million vs $150.673 million estimate.
- benzinga.com Neuronetics Sees Q3 Sales $37.000M-$39.000M vs $38.395M Est Neuronetics (NASDAQ:STIM) sees Q3 sales of $37.000 million-$39.000 million vs $38.395 million analyst estimate.
- benzinga.com Neuronetics Q2 EPS $(0.15) Misses $(0.08) Estimate, Sales $38.108M Beat $36.612M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.08) by 94.81 percent. This is a 54.55 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com Neuronetics Publishes Real-World Data Showing Antidepressant Effects Of NeuroStar TMS In Adolescents And Young Adults Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…